Director, HF Section, The MetroHealth System
Cardiology
Dr. Mark E. Dunlap, MD
|
|
Give Review
Mark Dunlap works in the field of Cardiology. He went to University of Tennessee College of Medicine. He received awards:"Best Doctors", "Fellow (FAHA)", "Best Research Clinical Paper", "Department of Medicine Teaching Excellence Award Honorable Mention", "Certificate of Appreciation Award, Advanced Clinic Access Initiative", "Federal Employee Recognition Award", "Finalist, Melvin L. Marcus Young Investigator Award in Cardiovascular Integrated Physiology", "IMHOTEP Society - Leadership Recognition", "Distinguished Student Service Award" and "Fellow (FACC)". Mark Dunlap has written publications. He has 56 publications published with PubMed. The lastest publication is: 'Autonomic Modulation in Heart Failure: Ready for Prime Time?'
Publications
- Autonomic Modulation in Heart Failure: Ready for Prime Time?
- Spironolactone for Heart failure with preserved ejection fraction.
- Heart failure notwithstanding ejection fraction (HFnEF)--a possible unifying hypothesis?
- Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial.
- Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for Heart failure: insights from the ASTRONAUT trial.
- Global variation in quality of care among patients hospitalized with Acute heart failure in an international trial: findings from the Acute study clinical effectivene...
- Fluid re-distribution rather than accumulation causes most cases of decompensated Heart failure.
- Chemohypersensitivity and autonomic modulation of venous capacitance in the pathophysiology of Acute decompensated heart failure.
- Treatment of anemia with darbepoetin alfa in systolic Heart failure.
- Effect of aliskiren on postdischarge mortality and Heart failure readmissions among patients hospitalized for Heart failure: the ASTRONAUT randomized trial.
- Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).
- 6-min walk test provides prognostic utility comparable to cardioPulmonary exercise testing in ambulatory outpatients with systolic heart failure.
- Anemia and iron deficiency in Heart failure.
- Efficiently doing the wrong thing.
- In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial).
- In memorium: Matthew N. Levy, MD: December 2, 1922-March 19, 2012.
- Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation.
- Doing the right thing.
- Evidence for impaired vagus nerve activity in Heart failure.
- Aortic diameter, wall stiffness, and wave reflection in systolic hypertension.
- Structural and electrical remodeling as therapeutic targets in Heart failure.
- Augmentation index and central Aortic stiffness in middle-aged to elderly individuals.
- New studies influencing treatment of Heart failure: 2006 update.
- Aldosterone antagonists in the treatment and prevention of Heart failure.
- Changes in aortic stiffness and augmentation index after Acute converting enzyme or vasopeptidase inhibition.
- Combination pharmacologic therapies for Heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?
- Treatment of Heart failure with a normal ejection fraction.
- Alpha7-nicotinic acetylcholine receptor subunit is not required for parasympathetic control of the Heart in the mouse.
- Management of heart failure with Pulmonary hypertension.
- Prevention of diminished parasympathetic control of the Heart in experimental Heart failure.
- Angiotensin-receptor blockers in Heart failure: evidence from the CHARM trial.
- Is Heart failure different on the two continents (North America and Europe)?
- Mechanisms of altered vagal control in Heart failure: influence of muscarinic receptors and acetylcholinesterase activity.
- Angiotensin II receptor blockers in the treatment of Heart failure.
- ACE inhibitors vs ARBs: is one class better for Heart failure.
- Renal hemodynamics in Heart failure: implications for treatment.
- The Heart failure clinic: a consensus statement of the Heart Failure Society of America.
- Incidence and predictors of hyperkalemia in patients with Heart failure: an analysis of the CHARM Program.
- Long-term trandolapril treatment is associated with reduced Aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy.
- Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction ...
- Characterization of health-related quality of life in Heart failure patients with preserved versus low ejection fraction in CHARM.
- Pulsatile hemodynamic effects of candesartan in patients with Chronic heart failure: the CHARM Program.
- Patient perception of the effect of treatment with candesartan in Heart failure. Results of the candesartan in Heart failure: assessment of reduction in mortality and ...
- Mortality and morbidity reduction with Candesartan in patients with Chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left vent...
- Denervation of vagal cardioPulmonary receptors by injection of kainic acid into the nodose ganglia in dogs.
- Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with Chronic heart failure: a cohort study from the Candesartan in Heart f...
- Ganglionic mechanisms contribute to diminished vagal control in Heart failure.
- Pulsatile hemodynamics in congestive Heart failure.
- Functional nicotinic acetylcholine receptors that mediate ganglionic transmission in cardiac parasympathetic neurons.
- The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial.
- DITPA (3,5-Diiodothyropropionic Acid), a thyroid hormone analog to treat Heart failure: phase II trial veterans affairs cooperative study.
- Effect of nesiritide in patients with Acute decompensated heart failure.
- Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study.
- Giant mitochondria in a cardiomyopathic Heart.
- Acute cardiovascular toxic effects of copper in anesthetized rabbits.
Schools
University of Tennessee Memphis College of Medicine amp Surgery
Med College Va
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- View All
Conditions Treated
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Ectasia
- Aortic Valve Disease
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Best Doctors
- Fellow (FAHA)
- Best Research Clinical Paper
- Department of Medicine Teaching Excellence Award Honorable Mention
- Certificate of Appreciation Award, Advanced Clinic Access Initiative
- Federal Employee Recognition Award
- Finalist, Melvin L. Marcus Young Investigator Award in Cardiovascular Integrated Physiology
- IMHOTEP Society - Leadership Recognition
- Distinguished Student Service Award
- Fellow (FACC)
Education
-
Virginia Commonwealth University Health System -
University of Tennessee College of Medicine
Hospital
-
MetroHealth Medical Center
Drug Facts
| NPI NUMBER | 1255342440 | |
| NPPES Provider LastName | DUNLAP | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 44113 | |
| NPPES Provider State | OH | |
| Specialty Description | Cardiology | |
| Total Claim Count | 1906.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1255342440 |
| Last Name Of The Provider | DUNLAP |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. Thomas J. Dresing, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tamouh Hamoud, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory T. Stefano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Russell E. Raymond, DO |
|
|
Dr. Chen Hoe Chow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravi N. Nair, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Miriam S. Jacob, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gus Theodos, MD |
|
|
Dr. Ajay Bhargava, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravish Sachar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Abraham D. Abernethy, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Gregory B. Atkins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sabe K. De, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Renzo Y. Loyaga-Rendon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suresh Keshavamurthy, MD
This Doctor is OpenDoctor Recommended.
|